Harnessing the power of the endocannabinoid system.

Our goal is to become a global leader in the development of safe and effective prescription medicines to treat serious and life-threatening human diseases and conditions. OCTs primary focus is on the drug development for indications in severe, chronic pain conditions, that are one of the biggest challenges facing society today.

 

Find out more

Our Approach

OCT utilises a range of compounds in drug development, including proprietary cannabinoid derivatives, natural phytocannabinoids and completely new chemical entities (NCEs) that target the endocannabinoid system. By utilising a range of inputs, OCT is creating a drug development portfolio that maximises the therapeutic potential of cannabinoids, long-term market value, and market exclusivity across all activities.

 

Find out more

Meet the Team

With experience across pharmaceutical operations, R&D, intellectual property, law and finance, OCTs team is committed to excellence. Together, we are passionate about delivering breakthrough therapies for life-threatening conditions with a significant unmet medical need.

 

Find out more

Recent news, reports & resources

 

All News

  • OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer as the business prepares for exciting new developments

    OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer

    28 July 2020 OCT Press Release
  • Cannabinoids in medicine part 5: Treating COVID-19

    17 June 2020 Open Access Government
  • Why the Government should continue to invest in Life Sciences post COVID-19

    Why the government should continue to invest in Life Sciences post COVID-19

    01 June 2020 OCT blog - John Lucas, COO

Get in touch

Oxford Cannabinoid Technologies Ltd
1 Maddox Street
London W1S 2PZ
UK

Find us on a map